Health News Releases

  • Today May 20
May 18, 2016 12:05
South Korea is first to approve next generation lung cancer treatment olmutinib (BI 1482694 / HM61713)
Olmutinib* (BI 1482694 / HM61713) has been approved in South Korea for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non
May 17, 2016 17:30
New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Broad Range of Patients with IPF
New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).
May 17, 2016 11:00
GNT Pharma Receives IND Approval for Phase II Clinical Trial for Stroke Patients with Endovascular Treatment with First in Class Multi-Target Neuroprotection Drug Neu2000
GNT Pharma (“GNTP”) announced that the Korea Ministry of Food and Drug Safety has approved the company's Investigational New Drug (IND) application to initiate a Phase II clinical study of Neu2000 in
Herbalife members take steps towards inspiring healthy active living.(Photo: Business Wire)
May 16, 2016 14:14
Herbalife Rallies its Network to Inspire Healthy Active Living in Bid to Combat Obesity in Asia Pacific
Herbalife, a global nutrition company, has concluded its annual Asia Pacific training event - Extravaganza 2016 - held in Singapore from May 13-15. This year’s event saw Herbalife rally 10,000 of its
May 13, 2016 10:50
Takeda Appoints New Chief Financial Officer, James Kehoe
Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) today announced the appointment of James Kehoe as Takeda’s new Chief Financial Officer and Corporate Officer, effective on June 15, 2016.
May 12, 2016 14:15
Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain
Boehringer Ingelheim will undertake the first prospective, randomised controlled study of a non-vitamin K antagonist oral anticoagulant (NOAC) in patients with blood clots in the veins or venous sinus
May 11, 2016 18:35
Boehringer Ingelheim: Nine out of 10 AF patients are concerned about stroke and many want to be part of OAC treatment decisions, new international survey shows
Nine out of 10 patients with atrial fibrillation (AF) surveyed were concerned about the risk of a stroke.[1] Oral anticoagulant (OAC) treatments are usually prescribed to reduce this risk3 and the vas
May 11, 2016 18:25
Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
Incyte Corporation (Nasdaq:INCY) and ARIAD Pharmaceuticals, Inc. (Nasdaq:ARIA) today announced the entry into a definitive agreement for Incyte to acquire ARIAD’s European operations. At the close of
May 11, 2016 13:15
JHL Biotech Opens Innovative Biosimilars Manufacturing Facility in China
JHL Biotech (JHL), a biopharmaceutical company, opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan,
May 11, 2016 11:35
Takeda Reports Results for Fiscal Year 2015 (April 2015 - March 2016) and Forecast for Fiscal Year 2016
FY2015: A year of turnaround to sustained growth; achieved full year management guidance · Underlying revenue up +3.4% (reported revenue growing +1.7% to 1,807.4 billion yen), led by strong performan
May 10, 2016 10:25
Illumina Registers MiSeqDx System in South Korea
Illumina, Inc. (NASDAQ: ILMN) today announced it has received a product approval certificate for the MiSeqDx® Instrument and the MiSeqDx Universal Kit with the Ministry of Food and Drug Safety (MFDS)
May 09, 2016 17:05
LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma
Boehringer Ingelheim today announced the enrolment of the first patient in the global Phase III trial evaluating the efficacy and safety of nintedanib in combination with pemetrexed/cisplatin, followe
May 09, 2016 14:10
Takeda Receives $38 Million Grant from the Bill & Melinda Gates Foundation to Support Polio Eradication in Developing Countries
Takeda Pharmaceutical Company Limited (TOKYO:4502), (“Takeda”) today announced a partnership with the Bill & Melinda Gates Foundation to support global polio eradication in developing countries. With
May 04, 2016 17:55
IMS Health and Quintiles to Merge
IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdings Inc. (NYSE:Q): This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/ho
May 03, 2016 20:50
First-Ever Published Study Proves House Wellness Foods’ Feed LP20® Increases Immunity, Productivity of Whiteleg shrimp [L. vannamei]
A study from Japan has shown for the first time that heat-treated lactobacillus, as found in House Wellness Foods Feed LP20®, is effective in supporting the immune system of the Whiteleg shrimp, rever
April 29, 2016 20:00
Ora® Appoints David Hollander, M.D., M.B.A., as Chief Medical Officer
Ora, Inc., the world’s leading partner for ophthalmic pharmaceutical and device development, announced today the appointment of David A. Hollander, M.D., M.B.A., as Chief Medical Officer and Senior Vi
April 29, 2016 13:00
Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of Medicine
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that results from the international, randomized, double-blind, placebo-controlled TOURMALINE-MM1 Phase 3 clinical study, evaluating on
April 28, 2016 16:00
Little Life Hack, “Berry” Big Benefit
Women today do it all and don’t have time to be slowed down by pesky infections like urinary tract infections (UTIs). Luckily, there’s a simple solution to stave off that unwelcome sensation, and it’s
April 28, 2016 14:00
Biogen Appoints Michael Ehlers Executive Vice President, Research and Development
Biogen (NASDAQ: BIIB) today announced the appointment of Michael Ehlers, M.D., Ph.D., as executive vice president, Research and Development. Dr. Ehlers will oversee Biogen’s global Research, Drug D
April 27, 2016 09:45
The Revolutionary Intraocular Lens - InFo Instant Focus© - Now Available with an Extended Power Range
The company Swiss Advanced Vision (SAV-IOL SA - www.sav-iol.com) announced the availability of the intraocular lens (IOL) InFo Instant Focus© indicated for the treatment of cataract after removal of t
April 26, 2016 10:45
Quintiles Receives Technology Security Award from IDG’s CSO Magazine for Fourth Consecutive Year
Quintiles, the world’s leading provider of biopharmaceutical services, announced today that it has been named to the 2016 CSO50 by IDG's CSO magazine. This award recognizes the company’s innovative id
April 22, 2016 13:35
One of France’s University Hospitals Adopts Masimo Radical-7®, Including SpHb®, PVI®, and SET® Pulse Oximetry
Masimo (NASDAQ: MASI) announced today that Centre Hospitalier Universitaire (CHU) de Limoges, in Limoges, France has installed Masimo’s Radical-7®, including noninvasive, continuous hemoglobin (SpHb®)
April 20, 2016 19:00
The American Society of Clinical Oncology® Endorses the WIN 2016 Symposium: Innovative Approaches to Improve Cancer Patient Outcomes
The WIN Consortium (WIN) is proud to announce that its symposium dedicated to “Innovative approaches to improve cancer patient outcomes” has been endorsed by the American Society of Clinical Oncology
April 20, 2016 17:15
Herbalife Named as Official Nutrition Sponsor for Vietnamese Athletes Bound for Rio 2016, Commits to New Five-Year Partnership with Vietnam Sports
Herbalife, a global nutrition company (NYSE: HLF), announced today that the Vietnam Olympic Committee (VOC) has named Herbalife Vietnam as the Official Nutrition Sponsor for Vietnamese athletes bound
April 20, 2016 14:15
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced plans to conduct two outcome trials investigating the diabetes medicine Jardiance® (empagliflozin) for the treatment of people
25 per page50 per page75 per page100 per page